| Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection J Eyquem, J Mansilla-Soto, T Giavridis, SJC van der Stegen, M Hamieh, ... Nature 543 (7643), 113-117, 2017 | 1755 | 2017 |
| CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade T Giavridis, SJC van der Stegen, J Eyquem, M Hamieh, A Piersigilli, ... Nature medicine 24 (6), 731-738, 2018 | 1108 | 2018 |
| Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells Z Zhao, M Condomines, SJC van der Stegen, F Perna, CC Kloss, ... Cancer cell 28 (4), 415-428, 2015 | 813 | 2015 |
| The pharmacology of second-generation chimeric antigen receptors SJC Van Der Stegen, M Hamieh, M Sadelain Nature reviews Drug discovery 14 (7), 499-509, 2015 | 555 | 2015 |
| Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling S Wilkie, MCI van Schalkwyk, S Hobbs, DM Davies, SJC van der Stegen, ... Journal of clinical immunology 32, 1059-1070, 2012 | 524 | 2012 |
| CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape M Hamieh, A Dobrin, A Cabriolu, SJC van der Stegen, T Giavridis, ... Nature 568 (7750), 112-116, 2019 | 495 | 2019 |
| Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4 S Wilkie, SE Burbridge, L Chiapero-Stanke, ACP Pereira, S Cleary, ... Journal of Biological Chemistry 285 (33), 25538-25544, 2010 | 212 | 2010 |
| Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice AC Parente-Pereira, J Burnet, D Ellison, J Foster, DM Davies, ... Journal of clinical immunology 31, 710-718, 2011 | 137 | 2011 |
| Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? SJC Van der Stegen, DM Davies, S Wilkie, J Foster, JK Sosabowski, ... The Journal of Immunology 191 (9), 4589-4598, 2013 | 131 | 2013 |
| Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells DM Davies, J Foster, SJC Van Der Stegen, AC Parente-Pereira, ... Molecular medicine 18, 565-576, 2012 | 122 | 2012 |
| HLA-independent T cell receptors for targeting tumors with low antigen density J Mansilla-Soto, J Eyquem, S Haubner, M Hamieh, J Feucht, N Paillon, ... Nature medicine 28 (2), 345-352, 2022 | 97 | 2022 |
| Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid AC Parente-Pereira, H Shmeeda, LM Whilding, CP Zambirinis, J Foster, ... The Journal of Immunology 193 (11), 5557-5566, 2014 | 64 | 2014 |
| Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted T cells combined with carboplatin AC Parente-Pereira, LM Whilding, N Brewig, SJC van der Stegen, ... The Journal of Immunology 191 (5), 2437-2445, 2013 | 61 | 2013 |
| CAR T-cell immunotherapy of MET-expressing malignant mesothelioma T Thayaparan, RM Petrovic, DY Achkova, T Zabinski, DM Davies, ... Oncoimmunology 6 (12), e1363137, 2017 | 53 | 2017 |
| Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells SJC van der Stegen, PL Lindenbergh, RM Petrovic, H Xie, MP Diop, ... Nature biomedical engineering 6 (11), 1284-1297, 2022 | 36 | 2022 |
| Engineered and banked iPSCs for advanced NK-and T-cell immunotherapies F Cichocki, SJC van der Stegen, JS Miller Blood 141 (8), 846-855, 2023 | 21 | 2023 |
| Use of retroviral-mediated gene transfer to deliver and test function of chimeric antigen receptors in human T-cells AC Parente-Pereira, S Wilkie, SJC van der Stegen, DM Davies, J Maher Journal of Biological Methods 1 (2), e7-e7, 2014 | 21 | 2014 |
| FT819: translation of off-the-shelf TCR-Less Trac-1XX CAR-T cells in support of first-of-kind phase I clinical trial C Chang, S Van der Stegen, M Mili, R Clarke, YS Lai, A Witty, ... Blood 134, 4434, 2019 | 20 | 2019 |
| T cells fail to develop in the human skin-cell explants system; an inconvenient truth B Meek, CHMJ Van Elssen, MJAJ Huijskens, SJC van der Stegen, ... BMC immunology 12, 1-14, 2011 | 15 | 2011 |
| Abstract LB-108: Generation of off-the-shelf TCR-less CAR-targeted cytotoxic T cells from renewable pluripotent cells for cancer immunotherapy RL Clarke, S Stegen, T Lee, J Mansilla-Soto, C Chang, J Sasaki, ... Cancer Research 78 (13_Supplement), LB-108-LB-108, 2018 | 9 | 2018 |
